'Reassuring Data' for Two Multiple Sclerosis Meds in Pregnancy
Two studies report few complications from continuing ocrelizumab and natalizumab into pregnancy, with high live birth rates, a decline in elective abortions, and few major congenital abnormalities in newborns.
Celia Oreja Guevara Sandra Thiel Department Of Neurology University Hospital San Carlos Ruhr University Bochum First Trimester Screening Program
Source: medscape.com